Development of an automated AAV capsid titer assay on a high-throughput platform

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Development of an automated AAV capsid titer assay on a high-throughput platform

In the quest to advance AAV vector production, the development of automated AAV capsid titer assays represents a significant leap forward in analytical methodologies. By adopting advanced analytical tools, the manufacturing industry can achieve greater reproducibility, improved productivity, and faster time to results.

This webinar will present a case study describing the evaluation of a high-throughput automated analytical immunoassay platform to accelerate and improve the screening of clones and media for higher capsid titers.

The key objective of the study was to assess the ability of an automated immunoassay platform to improve the current practice of accurately estimating capsid titers throughout manufacture and purification.

Attend the webinar to:

Discover an automated immunoassay platform designed for rapid and efficient process insights, using minimal sample volumes
Learn how automated assays can enhance the screening process to identify the best-performing clones and media conditions for higher full capsid production
Explore the use of automated systems to increase throughput while maintaining assay accuracy and precision

Matthew J.Lotti

Senior Research Associate II at Ultragenyx Pharmaceutical, Inc.

Matt Lotti is a Senior Research Associate II at Ultragenyx Pharmaceutical Inc., with over 15 years in biotechnology and marine science. Specializing in biotechnology/microbiology analytical method development, he excels in gene therapy, impurities analysis, and stability studies management. His extensive experience spans roles at Pfizer, Aushon BioSystems, and NOAA, among others. With a strong background in teaching and public outreach, Matt is dedicated to advancing scientific research and education.

John Chappell

Senior Global Scientific Support Manager at Gyros Protein Technologies

John Chappell has approximately 25 years of experience in the Contract Research industry supporting both preclinical and clinical drug development. He has specialized in supporting biological compounds from an analytical perspective e.g., pharmacokinetic, immunogenicity and biomarker analysis. He is particularly interested in validation requirements and ensuring that data generated will be acceptable to the regulatory authorities.

He has spoken at many international conferences on various topics including oligonucleotide analysis, biomarker analysis, immunogenicity and the analytical support of biosimilar programs.

John is currently Sr Global Scientific Support Manager for Gyros Protein Technologies where he is responsible for training the Field Application Team as well as implementing customer collaborations and scientific innovations. John has been a user of the Gyrolab system for over 10 years.

As a Fellow of the Royal Society of Chemistry, he was involved in the American Association of Pharmaceutical Scientists (AAPS) Biosimilar Committee that has published papers on Pharmacokinetic and anti-drug antibody assays.